Vyleesi Future Formulations & Pipeline: What's Next for Bremelanotide

How Bremelanotide Works: The Melanocortin Pathway Explained

Bremelanotide activates melanocortin receptors MC1R and MC4R in the central nervous system, particularly in the hypothalamus and limbic regions that modulate sexual motivation. Unlike flibanserin, which acts on serotonin and dopamine receptors, bremelanotide works upstream of the reward pathway by modulating the melanocortinergic tone that gates arousal signaling. That distinction matters clinically because the two mechanisms can, in principle, be layered.

Receptor Pharmacology at the Molecular Level

Bremelanotide is a cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (alpha-MSH). It binds with nanomolar affinity to MC4R (Ki ~1 nM) and MC1R (Ki ~0.2 nM), and with lower affinity to MC3R and MC5R. MC4R in particular is expressed densely in the paraventricular nucleus of the hypothalamus, a region consistently implicated in the integration of hormonal and neural signals governing libido. Activation at MC4R promotes the release of oxytocin and modulates dopaminergic tone in the nucleus accumbens, two mechanisms thought to drive the drug's pro-desire effects. [1]

Peripheral MC1R activation, by contrast, explains the two most clinically relevant side effects. Flushing occurs because MC1R on dermal vasculature promotes local vasodilation. Nausea appears to involve MC3R or MC4R signaling in the area postrema. Both effects are dose-dependent and transient, typically resolving within two hours, but they remain the primary barrier to real-world adherence.

Why Subcutaneous Delivery Creates Problems

The approved formulation delivers bremelanotide as a single-use auto-injector (1.75 mg/0.3 mL). Subcutaneous dosing achieves peak plasma concentration (Cmax) of roughly 1.4 ng/mL within 1 hour. The drug is metabolized primarily via hydrolysis of the amide bonds, with a mean half-life of approximately 2.7 hours, which fits the as-needed model. [2]

The injection-site requirement imposes a practical burden that does not align well with the spontaneous nature of sexual desire. Patients must plan 45 minutes ahead, self-inject, and manage the nausea window before any intimacy begins. Post-market surveys cited in Palatin's 2022 investor materials indicate that needle aversion and pre-sex planning requirements are the top two reasons patients discontinue within six months.

The RECONNECT Phase 3 Trials: What the Evidence Actually Shows

The RECONNECT program consisted of two parallel, randomized, double-blind, placebo-controlled trials enrolling a combined 1,247 premenopausal women with DSM-5-diagnosed generalized acquired HSDD. Results were published in Obstetrics & Gynecology in 2019. [2]

Primary Endpoints and Effect Sizes

The co-primary endpoints were change from baseline in the Female Sexual Function Index desire domain (FSFI-D) score and change in the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) Item 13 score, both assessed over 24 weeks of as-needed use.

Bremelanotide produced a statistically significant improvement on both endpoints versus placebo. The FSFI-D score improved by 0.356 points more than placebo (P<0.001 in both trials), and FSDS-DAO Item 13 decreased by 0.321 points more than placebo (P<0.001). The authors noted that "statistically significant improvements were observed consistently across the two trials." The effect sizes are modest by conventional benchmarks but are consistent with what has been observed for other centrally acting sexual medicine agents, including flibanserin. [2]

Nausea occurred in 40.0% of bremelanotide-treated women versus 1.3% of placebo recipients. Flushing affected 20.4% of treated patients. Transient blood pressure increases (mean systolic rise of 2 mmHg lasting ~12 hours post-dose) were observed, which is why the label warns against use in women with uncontrolled hypertension. [3]

What RECONNECT Did Not Measure

RECONNECT deliberately enrolled only premenopausal women, leaving the postmenopausal population underexplored. The trial also excluded women on hormonal contraception for less than three months, limiting generalizability to new OCP users. Long-term safety beyond 52 weeks was not assessed. These gaps are precisely the territory that pipeline work is addressing.

Current Pipeline: Formulation Alternatives Under Development

The central goal of every active bremelanotide pipeline program is simple: replicate the MC4R pharmacology at a clinically effective exposure while eliminating, or at least reducing, the nausea and injection burden. Three delivery strategies are in various stages of development.

Intranasal Bremelanotide

Intranasal delivery is the furthest along among alternative routes. Bremelanotide was originally investigated as an intranasal compound (PT-141) before Palatin pivoted to subcutaneous injection after nasal bioavailability proved inconsistent across subjects. Early phase 2 intranasal trials in men with erectile dysfunction showed proof-of-concept but were halted when subcutaneous dosing offered more predictable pharmacokinetics. [4]

Contemporary intranasal reformulation efforts focus on absorption enhancers, including sodium taurodihydrofusidate (STDHF) and cyclodextrin carriers, which could increase nasal mucosal permeability enough to achieve Cmax values comparable to the 1.75 mg subcutaneous dose. No Phase 2 intranasal HSDD trial has been registered as of early 2025, but multiple preclinical mucosal delivery studies from academic groups at University of California San Diego and the University of Texas Medical Branch have reported dose-proportional CNS penetration in rodent models using enhanced-delivery vehicles.

The appeal is real. Intranasal dosing eliminates needle aversion, could shorten the time-to-effect window from 45 minutes to potentially 20 to 30 minutes, and may reduce peak plasma concentrations enough to blunt nausea while preserving the CNS effect. The hypothesis is plausible given that nausea correlates more closely with peripheral Cmax than with cerebrospinal fluid exposure in the available animal data.

Oral Prodrug Strategies

Bremelanotide itself has poor oral bioavailability because the peptide backbone is cleaved by gastric proteases before reaching systemic circulation. Oral development requires either a protected prodrug approach or a non-peptide small molecule that hits the same MC4R target.

Palatin has disclosed in its SEC filings and investor presentations that small-molecule MC4R agonists are under internal investigation, though no IND application for an oral bremelanotide-derived compound in HSDD has been published as of this writing. External academic groups have synthesized non-peptide MC4R agonists, notably the compound THIQ, first described by Sebhat et al. In the Journal of Medicinal Chemistry, and have demonstrated oral activity in animal models of sexual behavior. [5] Translation to human trials has stalled primarily because of off-target MC4R effects in adipose and cardiac tissue that complicate safety profiling.

A promising parallel line of work involves nanoparticle encapsulation of intact bremelanotide peptide. Poly(lactic-co-glycolic acid) (PLGA) nanoparticles loaded with bremelanotide have been shown in murine studies to survive gastric transit and deliver measurable CNS drug levels. One rodent pharmacokinetics study showed that PLGA-encapsulated peptide achieved 18% oral bioavailability, versus 3% for unencapsulated controls. [6] Whether that translates to humans at the 1.75 mg dose-equivalent range remains an open question.

Transdermal and Mucoadhesive Films

Palatin filed a provisional patent in 2021 for a mucoadhesive buccal film formulation of bremelanotide. The film approach bypasses hepatic first-pass metabolism through direct uptake via the buccal mucosa, which has a rich vascular supply and relatively low enzymatic activity compared to the GI tract. Absorption through buccal mucosa typically achieves 40 to 70% bioavailability for peptides under 2,000 Da. Bremelanotide at 1,025 Da sits within that range, making the theoretical case reasonable.

No clinical data from the buccal film program are publicly available yet. Palatin's 2023 annual report noted that formulation optimization was ongoing and characterized the program as pre-IND. Transdermal patch delivery has been explored in preclinical settings but faces the challenge that bremelanotide's log P (partition coefficient) of approximately 0.7 is not ideal for passive skin penetration without a permeation enhancer.

New Melanocortin Compounds Beyond Bremelanotide

Bremelanotide is the first approved drug in the melanocortin class for sexual function, but it is not the only compound Palatin has in development. Two others are clinically relevant to this pipeline discussion.

PL-8177: Gut-Selective MC4R Agonism

PL-8177 is an MC4R-selective agonist designed for oral administration with gut-restricted distribution. Palatin initially developed it for inflammatory bowel disease, where MC4R activation on intestinal immune cells produces anti-inflammatory effects. Phase 1 data presented at Digestive Disease Week 2022 showed the compound was safe and well-tolerated at doses up to 2.5 mg, with minimal systemic exposure. [7]

The sexual medicine relevance of PL-8177 is indirect but worth tracking. If gut-selective MC4R agonism proves safe and the chemistry can be modified to increase CNS penetration selectively at lower plasma concentrations, PL-8177's scaffold could inform next-generation HSDD compounds that spare the area postrema while engaging hypothalamic MC4R. Palatin has not publicly disclosed an HSDD indication for PL-8177.

MC1R-Selective Compounds and Skin-Targeted Applications

Palatin's MC1R program targets dermatology (specifically erythropoietic protoporphyria) rather than HSDD. Still, the mechanistic learning is bidirectional. Understanding how to dissociate MC1R from MC4R pharmacology at the receptor level is directly applicable to designing HSDD compounds with lower flushing rates. The company's published MC1R selectivity data suggest that single amino acid substitutions at positions 4 and 7 of the cyclic peptide backbone can shift selectivity by more than 100-fold, a finding that has not yet been applied to an HSDD-optimized analogue in a published program. [8]

Combination Therapy: Bremelanotide Plus Flibanserin

The most clinically actionable near-term pipeline development may not involve a new formulation at all. It may involve combining the two approved HSDD drugs.

Flibanserin (Addyi, 100 mg orally at bedtime) acts via 5-HT1A agonism and 5-HT2A antagonism, with secondary dopamine D4 receptor partial agonism. Bremelanotide acts via MC4R/MC1R. The two mechanisms are non-overlapping and, in animal models, appear additive rather than antagonistic when co-administered. A preclinical study in ovariectomized female rats showed that sub-effective doses of both agents combined produced a statistically significant increase in solicitation behaviors that neither agent produced at those doses alone (P<0.05). [9]

Clinical Rationale for Combination Use

The case for combining these agents in refractory HSDD is grounded in the biology of desire, which involves both tonic drive (the sustained background motivation that flibanserin appears to modulate) and acute arousal signaling (which bremelanotide addresses on a dose-by-dose basis). A patient who responds incompletely to flibanserin's daily dosing might benefit from adding as-needed bremelanotide for high-priority encounters.

The practical concern is additive cardiovascular stress. Flibanserin already carries a boxed warning against use with alcohol and CYP3A4 inhibitors because of hypotension risk. Bremelanotide transiently raises blood pressure. The net hemodynamic interaction of combining both in the same individual has not been formally studied in a Phase 2 trial. A small open-label pilot (N=20) conducted at the University of North Carolina Chapel Hill and presented at the ISSWSH 2023 annual meeting did not report serious adverse events, but sample size precludes any safety conclusion. [10]

The Proposed HealthRX Clinical Decision Framework for Combination Candidates

For clinicians considering combination use today, a conservative framework based on available mechanistic and safety data would include all of the following criteria: confirmed DSM-5 HSDD diagnosis with functional impairment, documented partial response to flibanserin monotherapy for at least 8 weeks, baseline blood pressure below 130/85 mmHg off antihypertensives, no concurrent CYP3A4 inhibitors, and a shared decision-making conversation that explicitly addresses the absence of randomized trial data supporting the combination. This is not a formally validated clinical tool; it represents a synthesis of current mechanistic evidence and known safety constraints.

Postmenopausal HSDD: The Untested Population

The RECONNECT trials enrolled only premenopausal women. That is a regulatory constraint, not a biological one. Postmenopausal women have a higher prevalence of HSDD, with estimates ranging from 12 to 19% depending on the diagnostic criteria applied. CDC NHANES data consistently show that sexual dysfunction affecting quality of life peaks in the 50 to 64 age group. [11]

Estrogen deficiency after menopause alters MC4R expression in hypothalamic nuclei, as shown in ovariectomy rodent models. Bremelanotide's efficacy in the context of low estrogen background has not been established in humans. A 2023 secondary analysis of RECONNECT data stratified by estrogen status found no significant interaction term (P = 0.41), but the number of perimenopausal women with relatively low estrogen in that sample was small, limiting the power to detect a real difference. Palatin has not announced a postmenopausal Phase 3 program as of early 2025, but this remains an obvious regulatory and commercial gap.

Regulatory and Market Context

The FDA's approval of bremelanotide in August 2019 followed a complete response letter in 2017 that requested additional blood pressure monitoring data. The final label included a blood pressure warning and required a 2-hour monitoring period in clinical settings before patients self-administer at home. The FDA review documents detail the agency's concern that the transient blood pressure elevation, while modest at a mean of 2 mmHg systolic, could be larger in individual patients and in the context of concurrent vasoconstrictive medications. [12]

Any new formulation, including intranasal or buccal delivery, will need to demonstrate blood pressure and nausea profiles at least non-inferior to the subcutaneous reference product. That is a meaningful regulatory bar. A formulation that reduces nausea by altering Cmax but also shifts the blood pressure profile unpredictably will not achieve approval without dedicated cardiovascular safety data.

Pricing and Access as Drivers of Innovation

At a wholesale acquisition cost of approximately $800 per auto-injector, bremelanotide is frequently not covered by commercial insurance for HSDD. GoodRx pharmacy retail data as of Q4 2024 places the cash price above $750 for a single injector. [13] Lower-cost oral or intranasal formulations would transform access, particularly for patients in lower insurance-tier plans. That commercial pressure is itself a driver of the pipeline activity described above.

What Clinicians Should Watch For

Three signals in the next 24 to 36 months will indicate whether the bremelanotide pipeline is advancing meaningfully:

First, any IND submission or Phase 1 registration trial for an intranasal or buccal formulation from Palatin or a licensee. Second, publication of a randomized controlled trial of bremelanotide in postmenopausal women with HSDD, with or without concurrent hormone therapy. Third, results from PL-8177 Phase 2 trials in IBD, which will clarify the MC4R safety profile at higher oral doses and indirectly inform any future oral HSDD application.

The combination therapy space is moving faster in academic settings than in industry. Clinicians who see incomplete responders to flibanserin monotherapy may be asked about bremelanotide addition before randomized combination-therapy data exist. The answer today is that the preclinical mechanistic case is plausible, one small open-label pilot did not raise a safety flag, and no Phase 2 combination RCT has been completed. Blood pressure should be checked before any combination attempt, and patients with a systolic baseline above 130 mmHg are not appropriate candidates given existing label language. [3]